Physician profile
Lisa Haller
NPI 1245204858
$3,128.53
in general payments reported to CMS, 2019-2025
26 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $32.46 · 2021: $690 · 2022: $812 · 2023: $576 · 2024: $515 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $419.56 | 2021-2025 | Terlivaz, Acthar |
| Novartis Pharmaceuticals Corporation | $380.17 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $299.83 | 2019-2024 | Lokelma, Farxiga |
| Amgen INC. | $279.57 | 2019-2025 | Tavneos, Krystexxa |
| Novo Nordisk INC | $191.69 | 2023-2024 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $175.52 | 2021-2024 | Benlysta |
| Horizon Therapeutics Plc | $164.39 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $149.40 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $140.87 | 2022-2024 | |
| Opko Pharmaceuticals, LLC | $132.40 | 2021-2022 | |
| Vivus LLC | $120.29 | 2025 | Qsymia |
| Daiichi Sankyo INC. | $100.02 | 2019-2023 | Injectafer |
| Aurinia Pharma U.S., INC. | $99.55 | 2021 | |
| Travere Therapeutics, INC. | $75.38 | 2023 | |
| Alnylam Pharmaceuticals INC. | $67.80 | 2022-2023 | Onpattro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $63.33 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $49.56 | 2019-2024 | Crysvita |
| Akebia Therapeutics INC | $44.34 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.64 | 2022 | |
| Cycle Pharmaceuticals INC | $23.14 | 2025 | Venxxiva |
| Lilly USA, LLC | $21.99 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $21.64 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.67 | 2022 | |
| Calliditas Therapeutics US INC. | $18.13 | 2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $15.59 | 2025 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Haller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.